Achillion Pharmaceuticals (ACHN)
Achillion Pharmaceuticals Revenue Growth: 3729%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACHN Revenue Growth Rankings
| Overall | 99th percentile | 6 of 4399 |
| Sector | 99th percentile | 4 of 461 in Healthcare |
| Industry | 96th percentile | 4 of 126 in Biotechnology |
ACHN Revenue Growth Range, Past 5 Years
| Minimum | -97.22% | Sep 2008 |
| Maximum | 3729% | Mar 2012 |
| Average | 585.1% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ACHN related companies
ACHN News
$ACHN had a huge fall.....and has consolidated nicely. Should move up very well from here on its news. HF in here now too
about 2 days ago by taketheplunge
about 2 days ago by taketheplunge
News related to $ACHN, currently -5.6% since open: 'Achillion gets FDA incentives for hepatitis C drug' http://stks.co/3pmu
about 8 days ago by TradeBot
about 8 days ago by TradeBot
$ACHN up 7% in pre today but $IDIX still the better co. and both heating back up again lately while everyone distracted by $FB
about 8 days ago by QR_Winner
about 8 days ago by QR_Winner
EBR: Watchlist/worksheet/4 Trading Ideas: $OPTR $ACHN $BEAM $V http://stks.co/3pOI
about 8 days ago by TheEquitiesRoom
about 8 days ago by TheEquitiesRoom
ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
May 15, 7:02AM Benzinga
May 15, 7:02AM Benzinga
@WalkenTalken nailed this $soda. For his next trick maybe he can endorse some $ACHN for me. Find out his take on $PCLN $MCP
about 14 days ago by HTB_Krull
about 14 days ago by HTB_Krull
Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development
May 09, 7:00AM GlobeNewswire
May 09, 7:00AM GlobeNewswire
$achn now green too......what is going on in hep c world? $achn $idix
about 15 days ago by taketheplunge
about 15 days ago by taketheplunge
UPDATE: UBS Investment Research Upgrades Achillion to Neutral; Balanced Risk/Reward
May 07, 12:55PM Benzinga
May 07, 12:55PM Benzinga
RT @AaronM @Bleedblue sorry about that confusion.. I heart $ARNA.. $ACHN blows < stop reading AF's columns and go long bud!>
about 23 days ago by Bleedblue
about 23 days ago by Bleedblue
$ACHN Watch for > movement on ACHN: Why Did The Market Trip These Stocks Up? (ACHN, MVIS) http://stks.co/3UJG
about 29 days ago by bampotscot
about 29 days ago by bampotscot
$ACHN We need is a Clinical Analysis of data. Liisa Bayko does not understand the data:http://stks.co/3U7J
about 29 days ago by bampotscot
about 29 days ago by bampotscot
Baird Maintains an 'Outperform' on Achillion Pharmaceuticals (ACHN); Reassuring Clarification on '1625
Apr 23, 2:22PM Street Insider
Apr 23, 2:22PM Street Insider
Wells Fargo Maintains an 'Outperform' on Achillion Pharmaceuticals (ACHN); A Few Hiccups, But Expect Positive N-T Data
Apr 23, 12:27PM Street Insider
Apr 23, 12:27PM Street Insider
Achillion (ACHN) Updates on EQT Data from Segment 2 of ACH-1625 Phase 2a
Apr 23, 9:27AM Street Insider
Apr 23, 9:27AM Street Insider
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
JMP Securities Downgrades Achillion Pharmaceuticals (ACHN) to Market Perform
Apr 23, 8:08AM Street Insider
Apr 23, 8:08AM Street Insider
Achillion (ACHN) Presents Strong Data from ACH-1625 Phase 2a; Safety Profile Similar
Apr 23, 7:36AM Street Insider
Apr 23, 7:36AM Street Insider
Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
Apr 21, 4:00AM GlobeNewswire
Apr 21, 4:00AM GlobeNewswire
Baird Reiterates an 'Outperform' on Achillion Pharmaceuticals (ACHN); Buy on Weakness
Apr 19, 4:29PM Street Insider
Apr 19, 4:29PM Street Insider
UPDATE - UBS Initiates Coverage on Achillion Pharma (ACHN) with a Neutral; All-Oral Combo Already Priced In
Apr 12, 10:57AM Street Insider
Apr 12, 10:57AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACHN | 6.93 | -0.28 | -3.88% | 508.81M |
| ACGL | 38.58 | +0.10 | +0.26% | 5.211B |
| ACET | 8.10 | -0.34 | -4.03% | 226.19M |
| ACEL | None | None | None | |
| ACE | 72.53 | -0.19 | -0.26% | 24.52B |
| ACAT | 35.20 | -1.43 | -3.90% | 463.37M |
| ACAS | 9.01 | +0.05 | +0.56% | 2.992B |
| ACAD | 1.39 | +0.00 | +0.00% | 73.53M |
